Centre for Public Health
Belfast, Antrim, BT126BA, United Kingdom
NCT Number: NCT01778231
This study aims to investigate genetic and environmental determinants of macular pigment (MP) and assess the effects of lutein and zeaxanthin-rich supplements on macular pigment levels.
Looking for future studies?
Notify Me18 year–50 year
All sexes
Interventional
Not applicable
Belfast, Antrim, BT126BA, United Kingdom
Age-related macular degeneration is the leading cause of blindness in elderly people in western countries1. It is a degenerative condition of the macula characterized by the death or dysfunction of photoreceptors, leading to the progressive loss of central vision1. Central vision is needed for activities requiring fine vision such as reading, driving or recognizing faces. With the aging population and increasing expectations in health care it is therefore of utmost importance to preserve the quality of life and independence of the elderly through prevention of this ocular disease.
Much interest surrounds macular pigment due to its putative role in protecting the macula from oxidative stress and age-related degenerative change2, yet much is still unknown about factors that determine its uptake and deposition. Large inter-individual differences in MP have been demonstrated with several large population based studies showing that peak macular pigment density can vary by over a factor of 10 between individuals3-4. Subsequent studies have suggested a number of parameters such as age, diet, percentage body fat, gender and tobacco use5-9 as determinants of MP, however these only account for approximately a third of the variance leaving a significant proportion unexplained.
Lutein and Zeaxanthin (L and Z), constituents of MP, cannot be synthesized by the body and so are entirely dietary in origin. They are present in foods such as collard greens, spinach and Brussels sprouts10. Variation in the bitter-taste receptor gene, TAS2R38 confers the ability to taste 6-n-propylthiouracil (PROP) and phenylthiocarbamide (PTC) which is present in many of these foods11. People who taste PTC with a greater intensity are more likely to avoid these foods and therefore we hypothesize they may have lower levels of macular pigment. Thus, this study may help to identify a group at higher risk of macular degeneration.
Despite MP's dietary origin only modest correlations exist with serum and dietary levels of L and Z, and although the level of MP can be augmented in most people by diet or supplementation the response is variable and not always correlated with baseline level. Most supplementation studies identify a sub-group of "retinal non-responders"12 in which serum values of the carotenoids have risen, yet no change is found in macular pigment, the reason for this is not clear. The first part of our study will provide a well-phenotyped group in which to explore this further. Several studies have also shown that peak macular pigment levels are strongly heritable13-14 suggesting genetics may play an important role. Although no gene has currently been clearly identified the ApoE gene has been suggested to show an association with macular pigment level. A supplementation study in this population will be able to determine whether the genes identified on a cross-sectional basis do determine uptake of the nutritional supplement. We may also be able to identify specific demographic or lifestyle factors of non-responders which may help to explain the phenomenon.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Antioxidant and trace element supplement
Time frame: 16 weeks
Macular Pigment Measurement using Heterochromatic Flicker Photometry
Time frame: 16 weeks
Time frame: 16 weeks
Macular Pigment level measured using reflectometry
Queen's University, Belfast
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial DetailsNCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details